Overview

Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes

Status:
Completed
Trial end date:
2008-05-20
Target enrollment:
Participant gender:
Summary
Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. The purpose of this study is to assess the long term safety and effectiveness of vildagliptin, an unapproved drug, compared to that of glimepiride in lowering overall blood glucose levels when added to metformin in people with type 2 diabetes not at target blood glucose levels on metformin alone.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Glimepiride
Metformin
Vildagliptin